Nevertheless, the approval of drugs like burosumab for the treatment of hypophosphatemic rickets signifies a significant advancement in leveraging FGF23 modulation for therapeutic purposes, offering hope for patients afflicted with related disorders. The gene discussed is FGF23; the disease is Dent disease.